These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32665517)

  • 1. Psoriatic Plaques After Initiation of Dupilumab Therapy.
    DeGrazia TM; Raji K; Alshamekh S; Chisolm S
    Dermatitis; 2020; 31(4):e36-e37. PubMed ID: 32665517
    [No Abstract]   [Full Text] [Related]  

  • 2. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series.
    Napolitano M; Scalvenzi M; Fabbrocini G; Cinelli E; Patruno C
    Dermatol Ther; 2019 Nov; 32(6):e13142. PubMed ID: 31664761
    [No Abstract]   [Full Text] [Related]  

  • 3. Debut Of Inflammatory Bowel Disease Associated To Ixekizumab In Patient With Moderate, Difficult -To-Manage Psoriasis.
    Merino Gallego E; Gómez Torres K; Martínez Amate E
    Gastroenterol Hepatol; 2020 Dec; 43(10):622-623. PubMed ID: 32674878
    [No Abstract]   [Full Text] [Related]  

  • 4. A pediatric case of dupilumab-induced pustular psoriasis.
    Dang N; Zheng H; Ren Y
    J Dermatolog Treat; 2024 Dec; 35(1):2333016. PubMed ID: 38839072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Efficacy and Safety of Interleukin-17 Inhibitors in Treating Patients with Erythrodermic Psoriasis: A Retrospective Cohort, Three-Center Study.
    Lan Y; Wu X; Ni L; Liu Y; Yan T; Duan D; Zhang Z
    Am J Clin Dermatol; 2024 Sep; 25(5):857-859. PubMed ID: 38967901
    [No Abstract]   [Full Text] [Related]  

  • 6. Paradoxical reversed plantar involvement during ixekizumab therapy for psoriasis.
    Martínez-Doménech Á; García-Legaz-Martínez M; Magdaleno-Tapial J; Giácaman M; Hernández-Bel P; Pérez-Ferriols A
    Dermatol Online J; 2019 Apr; 25(4):. PubMed ID: 31046917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review.
    Almustafa ZZ; Weller K; Autenrieth J; Maurer M; Metz M
    Acta Derm Venereol; 2019 Sep; 99(10):905-906. PubMed ID: 31233177
    [No Abstract]   [Full Text] [Related]  

  • 8. Ixekizumab-induced paradoxical pustular reaction successfully treated with guselkumab.
    Hlaca N; Zagar T; Kastelan M; Brajac I; Prpic-Massari L
    Clin Exp Dermatol; 2021 Dec; 46(8):1572-1573. PubMed ID: 34028847
    [No Abstract]   [Full Text] [Related]  

  • 9. Dupixent® (Dupilumab): A Newly Approved Interleukin-4 Receptor Antagonist for the Treatment of Atopic Dermatitis in Pediatric Patients.
    Gupta AK; Love RP; Abramovits W; Vincent KD
    Skinmed; 2019; 17(2):107-109. PubMed ID: 31145061
    [No Abstract]   [Full Text] [Related]  

  • 10. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
    Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
    Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis.
    Mrowietz U; Riedl E; Winkler S; Xu W; Patel H; Agada N; Lebwohl MG
    J Am Acad Dermatol; 2020 Nov; 83(5):1436-1439. PubMed ID: 32526319
    [No Abstract]   [Full Text] [Related]  

  • 12. Paradoxical Arthritis Due to Ixekizumab in a Patient With Plaque Psoriasis.
    Vidal D; Ros S; Reina D
    Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):255-256. PubMed ID: 29861037
    [No Abstract]   [Full Text] [Related]  

  • 13. Ustekinumab associated with flares of psoriatic arthritis.
    Stamell EF; Kutner A; Viola K; Cohen SR
    JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute arthritis and arthralgia as an adverse drug reaction to dupilumab.
    de Wijs LEM; van der Waa JD; de Jong PHP; Hijnen DJ
    Clin Exp Dermatol; 2020 Mar; 45(2):262-263. PubMed ID: 31323136
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
    Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
    Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe Adult Atopic Dermatitis: Clinical Challenges.
    Russo F; Flori ML; Gola M; Milanesi N
    Dermatitis; 2020; 31(4):e48-e49. PubMed ID: 32209869
    [No Abstract]   [Full Text] [Related]  

  • 17. Nummular dermatitis on guselkumab for palmoplantar psoriasis.
    Truong A; Le S; Kiuru M; Maverakis E
    Dermatol Ther; 2019 Jul; 32(4):e12954. PubMed ID: 31070862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab.
    Ferrucci S; Tavecchio S; Berti E; Angileri L
    Clin Exp Dermatol; 2020 Jul; 45(5):625-626. PubMed ID: 32112580
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period.
    Megna M; Cinelli E; Balato A; Gallo L; Fabbrocini G
    J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):e152-e153. PubMed ID: 31715054
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.